{"id":63981,"date":"2026-11-09T09:55:35","date_gmt":"2026-11-09T09:55:35","guid":{"rendered":"https:\/\/ibima.eu\/?p=63981"},"modified":"2026-11-09T09:57:09","modified_gmt":"2026-11-09T09:57:09","slug":"treatyng-eu","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/treatyng-eu\/","title":{"rendered":"TREATYNG"},"content":{"rendered":"

[et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.27.6″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb25px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_row _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbTREating Arrhythmogenic cardiomyopathy by TargetIng neuropeptide-Y signaliNG.\u00bb _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#0C71C3″ module_alignment=\u00bbcenter\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb2_3,1_3″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb2_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_text _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n

\n
\n
\n
\n
\n
\n

Financed by<\/span><\/strong> : Instituto de Salud Carlos III (ISCIII)<\/span><\/span><\/p>\n

Program<\/strong>: ERDERA \u2013 Joint Transnational Call 2025 \u201cPreclinical therapy studies for rare diseases using small molecules and biologicals \u2013 development and validation\u201d<\/span><\/p>\n

Project National Reference:<\/strong> AC25\/00087<\/span><\/p>\n

Role in the project:<\/strong> Partner<\/span><\/p>\n

Duration:<\/b> May 2026 to April 2029<\/span><\/p>\n

\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n
\n
\n
\n

Contact: Jos\u00e9 Mar\u00eda P\u00e9rez Pomares<\/span><\/p>\n

Implementation Centre: IBIMA Platform BIONAND\u00a0<\/a><\/span><\/p>\n

Research group of IBIMA involved:\u00a0<\/a><\/span><\/span> Cardiovascular Development and Disease Research Group<\/span><\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2026\/10\/TREATYNG-PROVISIONAL.png\u00bb title_text=\u00bbTREATYNG PROVISIONAL\u00bb align=\u00bbright\u00bb _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb transform_scale=\u00bb162%|162%\u00bb transform_translate=\u00bb-14px|54px\u00bb width=\u00bb69%\u00bb max_width=\u00bb71%\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||-48px||false|false\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbAbstract\u00bb _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb0px||19px||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n

Arrhythmogenic cardiomyopathy (ACM) is a rare and potentially life-threatening heart disease, often affecting young individuals and athletes. It is characterized by the progressive loss of cardiac muscle cells and their replacement by fibrous and fatty tissue, which can lead to impaired cardiac function and life-threatening arrhythmias. Currently, there are no effective therapies capable of preventing or stopping disease progression.<\/span><\/p>\n

The TREATYNG project aims to develop new therapeutic strategies for ACM by investigating the role of neuro-cardiac communication, with a particular focus on Neuropeptide Y (NPY), a key co-transmitter of the sympathetic nervous system.<\/span><\/p>\n

Recent research suggests that sympathetic neurons play an active role in the development and progression of ACM through their interactions with different cardiac cell types. TREATYNG will investigate whether targeting abnormal NPY signalling can prevent or slow disease progression and reduce the risk of cardiac complications.<\/span><\/p>\n

Through an integrated approach combining in silico, molecular, cellular, in vivo and human cell-based studies, the project will explore the therapeutic potential of NPY-targeting agents, identify new therapeutic targets and develop prognostic biomarkers.<\/span><\/p>\n

The international consortium brings together researchers with complementary expertise in cardiovascular biology, neuroscience, pharmacology and translational research, as well as patient organisations. This collaborative approach aims to accelerate the development of innovative therapeutic strategies and improve the prognosis and quality of life of people living with arrhythmogenic cardiomyopathy.<\/span><\/p>\n

[\/et_pb_text][et_pb_heading title=\u00bbPartners\u00bb admin_label=\u00bbT\u00edtulo\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ custom_margin=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n

<\/a><\/p>\n